Estudo randomizado fase 2 | Uso profilático de garadacimabe em pacientes com angioedema hereditário.

Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial – The Lancet (link para o resumo – $ para o texto completo)

Comentário: Garadacimab significantly reduces frequency of hereditary angioedema exacerbations – Physician’s Weekly